BrainCo is developing an appetite-focused brain-stimulation wearable for a planned China-first launch, a potential move from its non-invasive brain-computer interface work into weight management, founding partner Nyx He told Bloomberg.
He said the company aims to bring the device to market within two to three years of his interview and is considering separate medical and consumer versions. Bloomberg reported that the United States could be a later market. The report gave no confirmed launch date.
He compared the concept to an “electronic version of GLP-1” obesity drugs. Bloomberg did not explain how the wearable would stimulate the brain, and the report did not establish that it uses the GLP-1 pathway.
The Food and Drug Administration (FDA) identifies semaglutide, Wegovy’s active ingredient, as a GLP-1 receptor agonist. The agency says GLP-1 regulates appetite and calorie intake. That information describes the drug pathway; it does not show how BrainCo’s proposed wearable would work.
BrainCo’s public website describes its work as non-invasive brain-computer interface technology but does not announce the appetite device. Bloomberg’s report provided no technical specifications, price, clinical results or safety data, and did not state the device’s regulatory status.
